Functional genomics of the 9p21.3 locus for atherosclerosis: Clarity or confusion?

Current Cardiology Reports

Volumn 16, Issue 7, 2014, Pages

  Chen, Hsiao Huei ^b   Almontashiri, Naif A M ^a   Antoine, Darlène ^a   Stewart, Alexandre F R ^a  

^a UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

^b OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

Author keywords

9p21.3 CAD risk locus; Atherosclerosis; Cell proliferation; Enhancers; Functional genomics; Macrophages; Vascular smooth muscle cells

Indexed keywords

PROTEIN TEAD; SMAD3 PROTEIN; TRANSCRIPTION FACTOR; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

CHROMATIN ASSEMBLY AND DISASSEMBLY; CHROMOSOME 9P; CORONARY ARTERY ATHEROSCLEROSIS; FOAM CELL; FUNCTIONAL GENOMICS; GENE LOCUS; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; HEART INFARCTION; HUMAN; LIVER CELL; MACROPHAGE; NONHUMAN; PATHOGENESIS; PHENOTYPE; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; ATHEROSCLEROSIS; CHROMOSOME 9; GENETICS; GENOMICS;

ATHEROSCLEROSIS; CHROMOSOMES, HUMAN, PAIR 9; GENOME-WIDE ASSOCIATION STUDY; GENOMICS; HUMANS; PHENOTYPE; SIGNAL TRANSDUCTION;

EID: 84901730451     PISSN: 15233782     EISSN: 15343170     Source Type: Journal    
DOI: 10.1007/s11886-014-0502-7     Document Type: Review

References (100)

1. 2011 [cited December 09, 2012]; Available at: http://www.who.int/ mediacentre/factsheets/fs310/en/index.html. Accessed 7 Sept 2013.
2. Prevalence of coronary heart disease - United States, 2006-2010. Morb Mortal Wkly Rep. 2011;60:1377-81.
3. Tuzcu EM, Kapadia SR, Tutar E, Ziada KM, Hobbs RE, McCarthy PM, et al. High prevalence of coronary atherosclerosis in asymptomatic teenagers and young adults: evidence from intravascular ultrasound. Circulation. 2001;103:2705-10. (Pubitemid 32538786)
4. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case - control study. Lancet. 2004;364:937-52. (Pubitemid 39208455)
5. Roberts R, Stewart AFR. Genes and coronary artery disease: where are we? J Am Coll Cardiol. 2012;60:1715-21.
6. Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature. 2007;447:661-78.
7. Helgadottir A, Thorleifsson G, Manolescu A, Gretarsdottir S, Blondal T, Jonasdottir A, et al. A common variant on chromosome 9p21 affects the risk of myocardial infarction. Science. 2007;316:1491-3. (Pubitemid 46906618)
8. McPherson R, Pertsemlidis A, Kavaslar N, Stewart A, Roberts R, Cox DR, et al.A common allele on chromosome 9 associated with coronary heart disease. Science. 2007;316:1488-91. (Pubitemid 46906617)
9. Deloukas P, Kanoni S, Willenborg C, Farrall M, Assimes TL, Thompson JR, et al. Large-scale association analysis identifies new risk loci for coronary artery disease. Nat Genet. 2013;45:25-33.
10. Anderson JL, Horne BD, Kolek MJ, Muhlestein JB, Mower CP, Park JJ, et al. Genetic variation at the 9p21 locus predicts angiographic coronary artery disease prevalence but not extent and has clinical utility. Am Heart J. 2008;156:1155-62, e2.
11. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837-47. (Pubitemid 28213628)
12. Ouimet M, Marcel YL. Regulation of lipid droplet cholesterol efflux from macrophage foam cells. Arterioscler Thromb Vasc Biol. 2012;32:575-81.
13. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105:1135-43. (Pubitemid 34212626)
14. Kim CJ, Khoo JC, Gillotte-Taylor K, Li A, Palinski W, Glass CK, et al. Polymerase chain reaction-based method for quantifying recruitment of monocytes to mouse atherosclerotic lesions in vivo: enhancement by tumor necrosis factor-alpha and interleukin-1 beta. Arterioscler Thromb Vasc Biol. 2000;20:1976-82. (Pubitemid 30644648)
15. Lessner SM, Prado HL, Waller EK, Galis ZS. Atherosclerotic lesions grow through recruitment and proliferation of circulating monocytes in a murine model. Am J Pathol. 2002;160:2145-55. (Pubitemid 34663406)
16. Swirski FK, Pittet MJ, Kircher MF, Aikawa E, Jaffer FA, Libby P, et al. Monocyte accumulation in mouse atherogenesis is progressive and proportional to extent of disease. Proc Natl Acad Sci U S A. 2006;103:10340-5. (Pubitemid 44051168)
17. Swirski FK, Libby P, Aikawa E, Alcaide P, Luscinskas FW, Weissleder R, et al. Ly-6Chi monocytes dominate hypercholesterolemia-associated monocytosis and give rise to macrophages in atheromata. J Clin Invest. 2007;117:195-205. (Pubitemid 46048466)
18. Tacke F, Alvarez D, Kaplan TJ, Jakubzick C, Spanbroek R, Llodra J, et al.Monocyte subsets differentially employ CCR2, CCR5, and CX3CR1 to accumulate within atherosclerotic plaques. J Clin Invest. 2007;117:185-94. (Pubitemid 46048465)
19. Combadiere C, Potteaux S, Rodero M, Simon T, Pezard A, Esposito B, et al. Combined inhibition of CCL2, CX3CR1, and CCR5 abrogates Ly6C(hi) and Ly6C(lo) monocytosis and almost abolishes atherosclerosis in hypercholesterolemic mice. Circulation. 2008;117:1649-57. (Pubitemid 351482605)
20. Saederup N, Chan L, Lira SA, Charo IF. Fractalkine deficiency markedly reduces macrophage accumulation and atherosclerotic lesion formation in CCR2-/- mice: evidence for independent chemokine functions in atherogenesis. Circulation. 2008;117:1642-8. (Pubitemid 351482604)
21. Robbins CS, Hilgendorf I, Weber GF, Theurl I, Iwamoto Y, Figueiredo JL, et al. Local proliferation dominates lesional macrophage accumulation in atherosclerosis. Nat Med. 2013;19:1166-72.
22. Sieweke MH, Allen JE. Beyond stem cells: self-renewal of differentiated macrophages. Science. 2013;342:1242974.
23. • Dandona S, Stewart AFR, Chen L, Williams K, So D, O'Brien E, et al.Gene dosage of the common variant 9p21 predicts severity of coronary artery disease. J Am Coll Cardiol. 2010;56:479-86. This study was the first to document that the 9p21.3 risk locus associates with atherosclerosis rather than myocardial infarction.
24. Patel RS, Su S, Neeland IJ, Ahuja A, Veledar E, Zhao J, et al. The chromosome 9p21 risk locus is associated with angiographic severity and progression of coronary artery disease. Eur Heart J. 2010;31:3017-23.
25. Chan K, Patel RS, Newcombe P, Nelson CP, Qasim A, Epstein SE, et al. Association between the chromosome 9p21 locus and angiographic coronary artery disease burden: a collaborative meta-analysis. J Am Coll Cardiol. 2013;61:957-70.
26. Bjorck HM, Lanne T, Alehagen U, Persson K, Rundkvist L, Hamsten A, et al. Association of genetic variation on chromosome 9p21.3 and arterial stiffness. J Intern Med. 2009;265:373-81.
27. Bown MJ, Braund PS, Thompson J, London NJ, Samani NJ, Sayers RD. Association between the coronary artery disease risk locus on chromosome 9p21.3 and abdominal aortic aneurysm. Circ Cardiovasc Genet. 2008;1:39-42.
28. Helgadottir A, Thorleifsson G, Magnusson KP, Gretarsdottir S, Steinthorsdottir V, Manolescu A, et al. The same sequence variant on 9p21 associates with myocardial infarction, abdominal aortic aneurysm and intracranial aneurysm. Nat Genet. 2008;40:217-24. (Pubitemid 351171400)
29. Thompson AR, Golledge J, Cooper JA, Hafez H, Norman PE, Humphries SE. Sequence variant on 9p21 is associated with the presence of abdominal aortic aneurysm disease but does not have an impact on aneurysmal expansion. Eur J Hum Genet. 2009;17:391-4.
30. Yasuno K, Bilguvar K, Bijlenga P, Low SK, Krischek B, Auburger G, et al. Genome-wide association study of intracranial aneurysm identifies three new risk loci. Nat Genet. 2010;42:420-5.
31. Foroud T, Koller DL, Lai D, Sauerbeck L, Anderson C, Ko N, et al. Genome-wide association study of intracranial aneurysms confirms role of Anril and SOX17 in disease risk. Stroke.2012;43:2846-52.
32. Murabito JM, White CC, Kavousi M, Sun YV, Feitosa MF, Nambi V, et al. Association between chromosome 9p21 variants and the ankle-brachial index identified by a meta-analysis of 21 genomewide association studies. Circ Cardiovasc Genet. 2012;5:100-12.
33. Emanuele E, Lista S, Ghidoni R, Binetti G, Cereda C, Benussi L, et al. Chromosome 9p21.3 genotype is associated with vascular dementia and Alzheimer's disease. Neurobiol Aging. 2011;32:1231-5.
34. Dichgans M, Malik R, Konig IR, Rosand J, Clarke R, Gretarsdottir S, et al. Shared genetic susceptibility to ischemic stroke and coronary artery disease: a genome-wide analysis of common variants. Stroke. 2014;45:24-36.
35. Ding H, Xu Y, Wang X, Wang Q, Zhang L, Tu Y, et al. 9p21 is a shared susceptibility locus strongly for coronary artery disease and weakly for ischemic stroke in Chinese Han population. Circ Cardiovasc Genet. 2009;2:338-46.
36. Gschwendtner A, Bevan S, Cole JW, Plourde A, Matarin M, Ross-Adams H, et al. Sequence variants on chromosome 9p21.3 confer risk for atherosclerotic stroke. Ann Neurol. 2009;65:531-9.
37. Matarin M, Brown WM, Singleton A, Hardy JA, Meschia JF. Whole genome analyses suggest ischemic stroke and heart disease share an association with polymorphisms on chromosome 9p21. Stroke. 2008;39:1586-9.
38. • Jarinova O, Stewart AFR, Roberts R, Wells G, Lau P, Naing T, et al. Functional analysis of the chromosome 9p21.3 coronary artery disease risk locus. Arterioscler Thromb Vasc Biol. 2009;29:1671-7. This study was the first to identify functional enhancers at the 9p21.3 risk locus.
39. •• Visel A, Zhu Y, May D, Afzal V, Gong E, Attanasio C, et al. Targeted deletion of the 9p21 noncoding coronary artery disease risk interval in mice. Nature. 2010;464:409-12. This study demonstrated that the 9p21.3 syntenic sequences in mouse chromosome 4 contain enhancer sequences that regulate CDKN2A and CDKN2B expression.
40. • Harismendy O, Notani D, Song X, Rahim NG, Tanasa B, Heintzman N, et al. 9p21 DNA variants associated with coronary artery disease impair interferon-gamma signalling response. Nature. 2011;470:264-8. This study proposed a mechanism whereby a SNP at the 9p21.3 locus confers risk for CAD. This study also demonstrated long-range effects of the enhancer sequences at the 9p21.3 locus, modifying chromatin structure in the vicinity of type 1 interferon genes, but see references 41, 42, and 81.
41. • Erridge C, Gracey J, Braund PS, Samani NJ. The 9p21 locus does not affect risk of coronary artery disease through induction of type 1 interferons. J Am Coll Cardiol. 2013;62:1376-81. This study failed to find an effect of the 9p21.3 locus on type 1 interferon expression in plasma of healthy donors or in monocyte-derived macrophages.
42. • Zollbrecht C, Grassl M, Fenk S, Hocherl R, Hubauer U, Reinhard W, et al. Expression pattern in human macrophages dependent on 9p21.3 coronary artery disease risk locus. Atherosclerosis. 2013;227:244-9. This study compared whole genome RNA expression profiles of monocyte-derived macrophages from 9p21.3-genotyped CAD patients and found no difference in type 1 interferon expression.
43. Pennacchio LA, Loots GG, Nobrega MA, Ovcharenko I. Predicting tissue-specific enhancers in the human genome. Genome Res. 2007;17:201-11. (Pubitemid 46220765)
44. • Fan M, Dandona S, McPherson R, Allayee H, Hazen SL, Wells GA, et al. Two chromosome 9p21 haplotype blocks distinguish between coronary artery disease and myocardial infarction risk. Circ Cardiovasc Genet. 2013;6:372-80. This study identified an additional haplotype at the 9p21.3 locus that associates with myocardial infarction in carriers of the 9p21.3 non-risk allele, consistent with reference 45.
45. • Musunuru K, Post WS, Herzog W, Shen H, O 'Connell JR, McArdle PF, et al. Association of single nucleotide polymorphisms on chromosome 9p21.3 with platelet reactivity: a potential mechanism for increased vascular disease. Circ Cardiovasc Genet. 2010;3:445-53. This study was the first to identify additional phenotypes tied to platelet reactivity in the vicinity of the 9p21.3 CAD risk locus.
46. Wong CH, Jenne CN, Petri B, Chrobok NL, Kubes P. Nucleation of platelets with blood-borne pathogens on Kupffer cells precedes other innate immunity and contributes to bacterial clearance. Nat Immunol. 2013;14:785-92.
47. Osman W, Low SK, Takahashi A, Kubo M, Nakamura Y. A genome-wide association study in the Japanese population confirms 9p21 and 14q23 as susceptibility loci for primary open angle glaucoma. Hum Mol Genet. 2012;21:2836-42.
48. Takamoto M, Kaburaki T, Mabuchi A, Araie M, Amano S, Aihara M, et al. Common variants on chromosome 9p21 are associated with normal tension glaucoma. PLoS One. 2012;7:e40107.
49. Wiggs JL, Yaspan BL, Hauser MA, Kang JH, Allingham RR, Olson LM, et al. Common variants at 9p21 and 8q22 are associated with increased susceptibility to optic nerve degeneration in glaucoma. PLoS Genet. 2012;8:e1002654.
50. Rajaraman P, Melin BS, Wang Z, McKean-Cowdin R, Michaud DS, Wang SS, et al.Genome-wide association study of glioma and meta-analysis. Hum Genet. 2012;131:1877-88.
51. Shete S, Hosking FJ, Robertson LB, Dobbins SE, Sanson M, Malmer B, et al. Genome-wide association study identifies five susceptibility loci for glioma. Nat Genet. 2009;41:899-904.
52. Parra EJ, Below JE, Krithika S, Valladares A, Barta JL, Cox NJ, et al. Genome-wide association study of type 2 diabetes in a sample from Mexico City and a meta-analysis of a Mexican-American sample from Starr County, Texas. Diabetologia. 2011;54:2038-46.
53. Manning AK, Hivert MF, Scott RA, Grimsby JL, Bouatia-Naji N, Chen H, et al.A genome-wide approach accounting for bodymass index identifies genetic variants influencing fasting glycemic traits and insulin resistance. Nat Genet. 2012;44:659-69.
54. Bosco A, Crish SD, Steele MR, Romero CO, Inman DM, Horner PJ, et al. Early reduction of microglia activation by irradiation in a model of chronic glaucoma. PLoS One. 2012;7:e43602.
55. Ebneter A, Casson RJ, Wood JP, Chidlow G.Microglial activation in the visual pathway in experimental glaucoma: spatiotemporal characterization and correlation with axonal injury. Invest Ophthalmol Vis Sci. 2010;51:6448-60.
56. Rivera-Zengotita M, Yachnis AT. Gliosis vs glioma? Don't grade until you know. Adv Anat Pathol. 2012;19:239-49.
57. Ajami B, Bennett JL, Krieger C, Tetzlaff W, Rossi FM. Local self-renewal can sustain CNS microglia maintenance and function throughout adult life. Nat Neurosci. 2007;10:1538-43. (Pubitemid 350175883)
58. Ehses JA, Perren A, Eppler E, Ribaux P, Pospisilik JA, Maor-Cahn R, et al. Increased number of islet-associated macrophages in type 2 diabetes. Diabetes. 2007;56:2356-70. (Pubitemid 47358243)
59. Kim JB, Deluna A, Mungrue IN, Vu C, Pouldar D, Civelek M, et al. Effect of 9p21.3 coronary artery disease locus neighboring genes on atherosclerosis in mice. Circulation. 2012;126:1896-906.
60. Kim TH, Abdullaev ZK, Smith AD, Ching KA, Loukinov DI, Green RD, et al. Analysis of the vertebrate insulator protein CTCF-binding sites in the human genome. Cell. 2007;128:1231-45. (Pubitemid 46427876)
61. Rodriguez C, Borgel J, Court F, Cathala G, Forne T, Piette J. CTCF is a DNA methylation-sensitive positive regulator of the INK/ARF locus. Biochem Biophys Res Commun. 2010;392:129-34.
62. Witcher M, Emerson BM. Epigenetic silencing of the p16(INK4a) tumor suppressor is associated with loss of CTCF binding and a chromatin boundary. Mol Cell. 2009;34:271-84.
63. Wallace JA, Felsenfeld G. We gather together: insulators and genome organization. Curr Opin Genet Dev. 2007;17:400-7. (Pubitemid 350016897)
64. Gaszner M, Felsenfeld G. Insulators: exploiting transcriptional and epigenetic mechanisms. Nat Rev Genet. 2006;7:703-13. (Pubitemid 44260006)
65. Phillips JE, Corces VG. CTCF: master weaver of the genome. Cell. 2009;137:1194-211.
66. Schalkwyk LC, Meaburn EL, Smith R, Dempster EL, Jeffries AR, Davies MN, et al. Allelic skewing of DNA methylation is widespread across the genome. Am J Hum Genet. 2010;86:196-212.
67. Shoemaker R, Deng J, Wang W, Zhang K. Allele-specific methylation is prevalent and is contributed by CpG-SNPs in the human genome. Genome Res. 2010;20:883-9.
68. Kim J, Kim JY, Song KS, Lee YH, Seo JS, Jelinek J, et al. Epigenetic changes in estrogen receptor beta gene in atherosclerotic cardiovascular tissues and in-vitro vascular senescence. Biochim Biophys Acta. 2007;1772:72-80.
69. Sharma P, Kumar J, Garg G, Kumar A, Patowary A, Karthikeyan G, et al. Detection of altered global DNA methylation in coronary artery disease patients. DNA Cell Biol. 2008;27:357-65. (Pubitemid 351969854)
70. Kotake Y, Nakagawa T, Kitagawa K, Suzuki S, Liu N, Kitagawa M, et al. Long noncoding RNA ANRIL is required for the PRC2 recruitment to and silencing of p15(INK4B) tumor suppressor gene. Oncogene. 2011;30:1956-62.
71. Yap KL, Li S, Munoz-Cabello AM, Raguz S, Zeng L, Mujtaba S, et al. Molecular interplay of the noncoding RNA ANRIL and methylated histone H3 lysine 27 by polycomb CBX7 in transcriptional silencing of INK4a. Mol Cell. 2010;38:662-74.
72. Vire E, Brenner C, Deplus R, Blanchon L, Fraga M, Didelot C, et al. The Polycomb group protein EZH2 directly controls DNA methylation. Nature. 2006;439:871-4. (Pubitemid 43255707)
73. Zhuang J, Peng W, Li H, Wang W, Wei Y, Li W, et al. Methylation of p15INK4b and expression of ANRIL on chromosome 9p21 are associated with coronary artery disease. PLoS One. 2012;7:e47193.
74. Krishnamurthy J, Torrice C, Ramsey MR, Kovalev GI, Al-Regaiey K, Su L, et al. Ink4a/Arf expression is a biomarker of aging. J Clin Invest. 2004;114:1299-307. (Pubitemid 40385301)
75. • Motterle A, Pu X, Wood H, Xiao Q, Gor S, Liang Ng F, et al. Functional analyses of coronary artery disease associated variation on chromosome 9p21 in vascular smooth muscle cells. Hum Mol Genet. 2012;21:4021-9. This study found that p15ink4b and p16ink4a expression is markedly reduced in arterial vascular smooth muscle cells and associated with high cell proliferation in carriers of the 9p21.3 risk allele.
76. Kia SK, Gorski MM, Giannakopoulos S, Verrijzer CP. SWI/SNF mediates polycomb eviction and epigenetic reprogramming of the INK4b-ARF-INK4a locus. Mol Cell Biol. 2008;28:3457-64. (Pubitemid 351657107)
77. Ottaviani D, Lever E, Mao S, Christova R, Ogunkolade BW, Jones TA, et al. CTCF binds to sites in the major histocompatibility complex that are rapidly reconfigured in response to interferon-gamma. Nucleic Acids Res. 2012;40:5262-70.
78. Hu G, Schones DE, Cui K, Ybarra R, Northrup D, Tang Q, et al. Regulation of nucleosome landscape and transcription factor targeting at tissue-specific enhancers by BRG1. Genome Res. 2011;21:1650-8.
79. Huang M, Qian F, Hu Y, Ang C, Li Z, Wen Z. Chromatin-remodelling factor BRG1 selectively activates a subset of interferon-alpha-inducible genes. Nat Cell Biol. 2002;4:774-81. (Pubitemid 35214771)
80. Cuddapah S, Cui K, Zhao K. Transcriptional enhancer factor 1 (TEF-1/TEAD1) mediates activation of IFITM3 gene by BRG1. FEBS Lett. 2008;582:391-7.
81. .• Almontashiri NA, Fan M, Cheng BL, Chen HH, Roberts R, Stewart AFR. Interferon-gamma activates expression of p15 and p16 regardless of 9p21.3 coronary artery disease risk genotype. J Am Coll Cardiol. 2013;61:143-7. This study showed that interferon gamma does elevate p15ink4b and p16ink4a expression, but that this occurs primarily through a post-transcriptional mechanism that is independent of the 9p21.3 risk genotype.
82. Argmann CA, Van Den Diepstraten CH, Sawyez CG, Edwards JY, Hegele RA, Wolfe BM, et al. Transforming growth factor-beta1 inhibits macrophage cholesteryl ester accumulation induced by native and oxidized VLDL remnants. Arterioscler Thromb Vasc Biol. 2001;21:2011-8. (Pubitemid 34219755)
83. Han J, Hajjar DP, Tauras JM, Feng J, Gotto Jr AM, Nicholson AC. Transforming growth factor-beta1 (TGF-beta1) and TGF-beta2 decrease expression of CD36, the type B scavenger receptor, through mitogen-activated protein kinase phosphorylation of peroxisome proliferator-activated receptor-gamma. J Biol Chem. 2000;275:1241-6. (Pubitemid 30051177)
84. Hu YW, Wang Q, Ma X, Li XX, Liu XH, Xiao J, et al. TGF-beta1 up-regulates expression of ABCA1, ABCG1 and SR-BI through liver X receptor alpha signaling pathway in THP-1 macrophage-derived foam cells. J Atheroscler Thromb. 2010;17:493-502.
85. Tashiro H, Shimokawa H, Sadamatu K, Yamamoto K. Prognostic significance of plasma concentrations of transforming growth factor-beta in patients with coronary artery disease. Coron Artery Dis. 2002;13:139-43. (Pubitemid 34747960)
86. Lievens D, Habets KL, Robertson AK, Laouar Y, Winkels H, Rademakers T, et al. Abrogated transforming growth factor beta receptor II (TGFbetaRII) signalling in dendritic cells promotes immune reactivity of T cells resulting in enhanced atherosclerosis. Eur Heart J. 2013;34:3717-27.
87. Reifenberg K, Cheng F, Orning C, Crain J, Kupper I, Wiese E, et al. Overexpression of TGF-b1 in macrophages reduces and stabilizes atherosclerotic plaques in ApoE-deficient mice. PLoS One. 2012;7:e40990.
88. Diez-Juan A, Perez P, Aracil M, Sancho D, Bernad A, Sanchez-Madrid F, et al. Selective inactivation of p27(Kip1) in hematopoietic progenitor cells increases neointimal macrophage proliferation and accelerates atherosclerosis. Blood. 2004;103:158-61. (Pubitemid 38029933)
89. Fan K, Ruan Q, Sensenbrenner L, Chen B. Transforming growth factor-beta 1 bifunctionally regulates murine macrophage proliferation. Blood. 1992;79:1679-85.
90. Hannon GJ, Beach D. p15INK4B is a potential effector of TGF-beta-induced cell cycle arrest. Nature. 1994;371:257-61.
91. Reynisdottir I, Polyak K, Iavarone A, Massague J. Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-beta. Genes Dev. 1995;9:1831-45.
92. Vijayachandra K, Higgins W, Lee J, Glick A. Induction of p16ink4a and p19ARF by TGFbeta1 contributes to growth arrest and senescence response in mouse keratinocytes. Mol Carcinog. 2009;48:181-6.
93. Brown KA, Pietenpol JA, Moses HL. A tale of two proteins: differential roles and regulation of SMAD2 and SMAD3 in TGF-beta signaling. J Cell Biochem. 2007;101:9-33. (Pubitemid 46652569)
94. MacLellan WR, Lee TC, Schwartz RJ, Schneider MD. Transforming growth factor-b response elements of the skeletal a-actin gene. Combinatorial action of serum response factor, YY1, and the SV40 enhancer-binding protein, TEF-1. J Biol Chem. 1994;269:16754-60.
95. Leask A, Holmes A, Black CM, Abraham DJ. Connective tissue growth factor gene regulation. Requirements for its induction by transforming growth factor-beta 2 in fibroblasts. J Biol Chem. 2003;278:13008-15. (Pubitemid 36800068)
96. Fujii M, Toyoda T, Nakanishi H, Yatabe Y, Sato A, Matsudaira Y, et al. TGF-beta synergizes with defects in the Hippo pathway to stimulate human malignant mesothelioma growth. J Exp Med. 2012;209:479-94.
97. Beyer TA, Weiss A, Khomchuk Y, Huang K, Ogunjimi AA, Varelas X, et al. Switch enhancers interpret TGF-beta and Hippo signaling to control cell fate in human embryonic stem cells. Cell Rep. 2013;5:1611-24.
98. .• Zheng Y, Devitt C, Liu J, Mei J, Skapek SX. A distant, cis-acting enhancer drives induction of Arf by Tgfbeta in the developing eye. Dev Biol. 2013;380:49-57. This article shows the requirement for the 9p21.3 syntenic region in mouse chromosome 4 for TGFβ-dependent activation of p14ARF from the CDKN2A gene.
99. Stewart AFR, Larkin SB, Farrance IKG, Mar JH, Hall DE, Ordahl CP. Muscle-enriched TEF-1 isoforms bind M-CAT elements from muscle-specific promoters and differentially activate transcription. J Biol Chem. 1994;269:3147-50. (Pubitemid 24237621)
100. Gray LT, Fong KK, Pavelitz T, Weiner AM. Tethering of the conserved piggyBac transposase fusion protein CSB-PGBD3 to chromosomal AP-1 proteins regulates expression of nearby genes in humans. PLoS Genet. 2012;8:e1002972.